UroGen Pharma 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, so welcome to this next fireside chat with UroGen Pharma. It is my great pleasure to welcome Liz Barrett, President and CEO, as well as Chris Degnan, Chief Financial Officer. Welcome. Thanks for joining us today.
Thanks. Thanks for having us.
Thanks, Michael. Liz, UroGen is in a very important phase of a company's life cycle, completing the early stages of the ZUSDURI launch.
You are expanding your pipeline. Why don't we start with just a big picture question, and how do you think UroGen is positioned heading into 2027?
Yeah. Great question. Obviously, happy to be here and sharing our story, and it has been a long storied past, getting to where we are today, but what an exciting time for us as a company, to your point. We launched our bladder cancer drug about a year ago, but got our permanent J-code the beginning of this year, so we really see this as our first year launch. It has just been an exciting time for us. It has been a great year in the launch of ZUSDURI. We have a smaller drug called JELMYTO that is on the market, so we have two commercial products. To your point, we also have a pipeline, and we are excited about where we are going, both as leaders in urothelial cancers, but also developing a long-term sustainable growth company.
We have settled on our strategic plan with our board, excited about the fact that we not only see great growth in the near term, but we also see a path to continued leadership and growth for the long term. That is what we are here to do. We are here to build a long-term sustainable growth company, both for patients, impacting patients, and for our shareholders to be able to see that we can continue to grow for the long haul. Again, exciting time for our company as we shift from a really a clinical stage to a commercial and clinical stage company. That is sort of how we are looking as we get into 2027 and beyond.
Yeah. Maybe a few questions on ZUSDURI. The permanent J-code has had a real impact on uptake and growth trajectory, early this year. As you stand today, and you just reported third quarter earnings, recently, maybe comment a bit about how ZUSDURI is being adopted, what types of patients are using the drug in the life cycle of a NMIBC patient, and what are the main drivers of additional growth?
Yeah, sure. I will ask Chris to start, and I will comment, add commentary.
Yeah. You mentioned the J-code. The J-code is certainly important here, and I think what is also important with ZUSDURI is we are the first FDA-approved product in the space, right? We are changing the treatment paradigm, where urologists for these patients and what they are dealing with in their intermediate risk space is multiple recurrences. Patients will come in, they will have a surgery, and then unfortunately, a lot of these patients will constantly recur. For us, it is, one, getting urologists to understand the value proposition that we have in terms of the clinical profile of the drug, but then also for them to understand how to change their practice in terms of getting them to use it from an operational workflow perspective, and then also confidence for them in terms of the reimbursement profile.
The good news for us is we have really strong reimbursement, with over 95% of covered lives having access to the drug. Urologists tend to be slower to adopt. They do not have a whole lot of familiarity with buy and bill, and for us, it is getting them to first try the product. What they are typically doing is they are trying it on one or two patients. They will see how it works from an operational perspective, they will make sure they have the reimbursement, and then they start to expand their adoption. We think about where we are for the launch. We have 6,500 core targets that we are focused on. We are still in the early stages of getting them first to try the product. Through September this year, we have over 650 physicians that have now tried ZUSDURI.
We are making good progress, but we are still early in terms of getting physicians to try the drug. The other thing that we are really focused on is how many of these physicians become adopters or repeat writers. Once they get confidence in the profile of the drug, once they get confidence that they are getting reimbursed as they would expect, starting then to treat multiple patients. We are also really pleased to see how many writers are becoming repeat writers. We are making good steady progress on both fronts.
What are you seeing so far on repeat usage? It seems like a lot of growth is driven by adding new prescribers to your funnel, but what are you seeing in terms of reusing and the same docs prescribing?
Yeah. Actually, I know you guys don't see this level of data, but the depth is what's been driving our revenue so far, and that is, you do have this group of champions and real adopters who have adopted it for the majority of their patients. It's your typical curve, right? You have those that are early adopters. They really buy into it. They say, "This is the way I'm going to treat my patients," and they adopt it for the majority of their patients. Then you have others on the other end that Chris was talking about that either haven't tried it yet or, "Oh, I'm going to try it on one patient and make sure that all of the things go right before I do." The good news is that the early adopters are driving depth.
Our revenue so far has come from a lot of these big adopters. As we go forward, we'll continue to do that, but we need to continue to get the breadth of users because as Chris said, we only have 660 out of the 6,000, so still a long way to go, there. Look, as we drive into 2027, not only are we engaging the patients, ensuring that physicians try the medicine, because 100% of the docs in our ATU that tried it said they will use it again. We have to make sure that they're helping them to identify these patients and really going from trialist to true adopters.
Right. In the third quarter, you reported $68 million sales on 35% growth. Can you comment on how much of that was driven by new prescriptions versus repeat use?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
